
Tirzepatide 5 mg Injection | Once-Weekly Prescription Medicine for Type 2 Diabetes
Phoenix Exim β Pharmaceutical Exporter from Nagpur, India
Phoenix Exim offers pharmaceutical products from Nagpur, India for international B2B requirements, including markets such as USA, UK, Australia, Singapore, Canada, South Korea, and UAE, subject to applicable import, registration, prescription, labeling, customs, and regulatory requirements.
1. π GENERAL INFORMATION
Mounjaro 5 mg Prefilled Pen contains tirzepatide 5 mg, a once-weekly injectable medicine belonging to the GIP and GLP-1 receptor agonist class.
In the U.S. prescribing information, Mounjaro is indicated as an adjunct to diet and exercise to improve blood-glucose control in adults with type 2 diabetes mellitus.
Tirzepatide works through two incretin pathways, helping regulate glucose-dependent insulin secretion, glucagon levels, food intake, and body weight.
β¦ Product Highlights
Active Ingredient: Tirzepatide
Strength: 5 mg
Dosage Form: Injection
Device: Prefilled Pen
Route: Subcutaneous injection
Frequency: Once weekly
Therapeutic Class: GIP / GLP-1 receptor agonist
Manufacturer/Brand: Mounjaro
Supply Base: Nagpur, Maharashtra, India
2. π PRODUCT INFORMATION
| Product Detail | Information |
|---|---|
| Brand Name | Mounjaro |
| Active Ingredient | Tirzepatide |
| Strength | 5 mg |
| Dosage Form | Injectable Solution |
| Presentation | Prefilled Pen |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Therapeutic Category | GIP / GLP-1 Receptor Agonist |
| Primary U.S. Indication | Type 2 Diabetes Mellitus |
| Country of Supply | India |
| Exporter | Phoenix Exim |
| Supply Location | Nagpur, Maharashtra, India |
The FDA labeling identifies Mounjaro as a clear, colorless to slightly yellow, sterile solution for subcutaneous use. The 5 mg presentation contains 5 mg tirzepatide in 0.5 mL in the U.S. labeling.
3. π― USES OF MOUNJARO 5 MG
πΉ Type 2 Diabetes Management
Mounjaro is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
πΉ Blood-Glucose Control
Tirzepatide helps regulate glucose metabolism through glucose-dependent effects on insulin and glucagon.
πΉ Appetite & Food Intake
Tirzepatide can reduce food intake and is associated with reductions in body weight in patients with type 2 diabetes.
Important: The approved indications and product labeling can differ between countries. Buyers should always check the current authorization in their destination market.
4. β BENEFITS OF MOUNJARO 5 MG
When appropriately prescribed and used, tirzepatide may provide several therapeutic benefits:
β
Helps improve blood-glucose control
β
Works through both GIP and GLP-1 receptor pathways
β
Enhances glucose-dependent insulin secretion
β
Reduces glucagon levels in a glucose-dependent manner
β
Helps reduce food intake
β
Can contribute to body-weight reduction
β
Convenient once-weekly administration
β
Available in a prefilled injection presentation
Tirzepatide's dual GIP/GLP-1 activity distinguishes it pharmacologically from medicines that activate only one of these incretin pathways.
5. β οΈ SIDE EFFECTS OF MOUNJARO 5 MG
Mounjaro can cause gastrointestinal and other adverse reactions.
Possible side effects include:
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Indigestion / dyspepsia
Abdominal pain
Injection-site reactions
The FDA prescribing information identifies nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain among the most common adverse reactions.
Some adverse reactions may be more noticeable during dose escalation.
6. πΈ COMMON SIDE EFFECTS
The commonly reported reactions include:
Nausea | Diarrhea | Decreased Appetite | Vomiting | Constipation | Dyspepsia | Abdominal Pain
These effects can vary in intensity between individuals.
If severe or persistent gastrointestinal symptoms occur, medical advice should be sought.
7. π HOW TO USE MOUNJARO 5 MG PREFILLED PEN
Mounjaro is administered subcutaneously once weekly according to the prescribing instructions. The U.S. label specifies injection into the abdomen, thigh, or upper arm, with injection sites rotated.
General Administration
STEP 1 β Check the Pen
Inspect the pen according to the manufacturer's instructions before use.
STEP 2 β Select Injection Site
The approved injection sites include the abdomen, thigh, or upper arm.
STEP 3 β Administer Subcutaneously
Inject under the skin, not into a vein or muscle.
STEP 4 β Follow the Prescribed Schedule
Mounjaro is generally administered once weekly. The exact dose-escalation schedule should be determined by the prescribing healthcare professional.
STEP 5 β Rotate Injection Sites
Rotate injection locations to reduce repeated irritation at the same site.
The U.S. prescribing information recommends 2.5 mg once weekly as the starting dose, followed by 5 mg once weekly after four weeks; further increases, when needed, are made in 2.5 mg increments after at least four weeks at the current dose.
β οΈ Important
Do not change the dose or injection schedule without medical supervision.
8. βοΈ HOW DOES MOUNJARO WORK?
Mounjaro contains tirzepatide, which activates both the GIP receptor and GLP-1 receptor.
𧬠Dual Incretin Action
Tirzepatide activates two incretin pathways involved in glucose regulation.
π Supports Insulin Secretion
It enhances first- and second-phase insulin secretion in a glucose-dependent manner.
π Reduces Glucagon
Tirzepatide reduces glucagon levels in a glucose-dependent manner.
π½οΈ Influences Food Intake
The medicine decreases food intake and is associated with reductions in body weight in people with type 2 diabetes.
π Prolonged Action
Its molecular structure includes a fatty-acid component that supports albumin binding and contributes to its prolonged half-life, allowing once-weekly administration.
9. π‘οΈ SAFETY ADVICE
β οΈ Thyroid Tumor Warning
Mounjaro carries a boxed warning regarding the risk of thyroid C-cell tumors observed in rats. The human relevance is unknown.
It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
π©Ί Pancreatitis
Acute pancreatitis has been observed. Seek medical evaluation if symptoms suggestive of pancreatitis occur.
π½οΈ Gastrointestinal Problems
Mounjaro can cause gastrointestinal adverse reactions and is not recommended for patients with severe gastroparesis.
π§ Kidney Function
Significant gastrointestinal reactions can contribute to dehydration and may lead to acute kidney injury. Appropriate medical monitoring may be required.
π Hypoglycemia
The risk of hypoglycemia can increase when Mounjaro is used with insulin or insulin secretagogues.
π¦ Gallbladder Problems
Acute gallbladder disease has been reported. Seek medical evaluation if symptoms suggestive of gallbladder disease occur.
ποΈ Diabetic Retinopathy
Patients with a history of diabetic retinopathy may require monitoring for progression.
π€° Pregnancy
Mounjaro may cause fetal harm based on animal studies. Discuss pregnancy, pregnancy planning, or breastfeeding with a healthcare professional before treatment.
π Oral Medicines
Because tirzepatide delays gastric emptying, it can potentially affect absorption of certain oral medicines.
π₯ Surgery / Anesthesia
Patients should inform healthcare professionals about Mounjaro treatment before planned surgery or procedures involving general anesthesia or deep sedation because delayed gastric emptying may increase aspiration risk.
βοΈ Storage
For the U.S. single-dose pen presentation, Mounjaro should generally be refrigerated at 2Β°Cβ8Β°C (36Β°Fβ46Β°F). If necessary, a single-dose pen may be kept at temperatures up to 30Β°C (86Β°F) for up to 21 days. Do not freeze. Keep it in the original carton to protect it from light.
Always follow the storage instructions supplied with the specific product presentation.
10. β FREQUENTLY ASKED QUESTIONS
Q1. What is Mounjaro 5 mg?
Mounjaro 5 mg is an injectable medicine containing tirzepatide 5 mg, administered subcutaneously.
Q2. What is Mounjaro used for?
In the U.S., Mounjaro is indicated with diet and exercise to improve blood-glucose control in adults with type 2 diabetes.
Q3. How often is Mounjaro 5 mg administered?
Mounjaro is administered once weekly according to the prescribed treatment schedule.
Q4. Where is Mounjaro injected?
It is injected subcutaneously into the abdomen, thigh, or upper arm, with injection sites rotated.
Q5. Is Mounjaro a GLP-1 medicine?
Tirzepatide activates both GIP and GLP-1 receptors, so it is a dual GIP/GLP-1 receptor agonist.
Q6. What are the common side effects?
Common adverse reactions include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
Q7. Can Mounjaro be used with insulin?
It may be used in certain treatment plans, but concomitant use with insulin can increase the risk of hypoglycemia. Dose adjustments may be required under medical supervision.
Q8. Who should not use Mounjaro?
It is contraindicated in people with a personal or family history of MTC, MEN 2, or a serious hypersensitivity to tirzepatide or its ingredients.
Q9. Does Mounjaro require refrigeration?
The U.S. single-dose pen should generally be refrigerated at 2Β°Cβ8Β°C. Specific temporary room-temperature allowances apply according to the U.S. labeling.
Q10. Can Mounjaro 5 mg be exported internationally?
International pharmaceutical requirements differ by country. Buyers should verify registration, prescription status, import authorization, cold-chain requirements, labeling, documentation, customs procedures, and applicable destination-country regulations before purchasing.
11. π SUBSTITUTE / ALTERNATIVES FOR MOUNJARO 5 MG
There is no universal one-to-one substitute for Mounjaro 5 mg.
Potential therapeutic alternatives may include medicines from related or different classes, depending on the patient's diagnosis and treatment plan, such as:
Other tirzepatide-containing products where legally approved
GLP-1 receptor agonist medicines
Other glucose-lowering medicines
Insulin-based therapies
Other physician-selected treatments for type 2 diabetes
β οΈ Important
A different medicine, active ingredient, strength, or formulation is not automatically equivalent to Mounjaro 5 mg.
Any substitution should be determined by a qualified healthcare professional based on the patient's medical history, glucose control, other medicines, contraindications, and applicable local prescribing guidance.
12. π SEO KEYWORDS
π Primary Product Keywords
Mounjaro 5 mg Prefilled Pen
Mounjaro 5 mg Injection
Mounjaro 5 mg Pen
Tirzepatide 5 mg Injection
Tirzepatide 5 mg Pen
Mounjaro 5 mg supplier
Mounjaro 5 mg exporter India
Tirzepatide injection supplier
Tirzepatide pharmaceutical exporter
Mounjaro pharmaceutical supplier
π International B2B Keywords
Mounjaro 5 mg exporter from India
Tirzepatide 5 mg supplier India
Tirzepatide injection exporter India
Mounjaro prefilled pen supplier
Tirzepatide prefilled pen exporter
Injectable diabetes medicine supplier India
Diabetes medicine B2B exporter
Pharmaceutical injection exporter Nagpur
Tirzepatide international supplier
Mounjaro pharmaceutical export India
π Country-Focused Keywords
Mounjaro supplier USA
Mounjaro supplier UK
Mounjaro supplier Australia
Mounjaro supplier Canada
Mounjaro supplier Singapore
Mounjaro supplier South Korea
Mounjaro supplier UAE
Tirzepatide supplier USA
Tirzepatide supplier UK
Tirzepatide supplier Australia
Tirzepatide supplier Canada
Tirzepatide supplier Singapore
Tirzepatide supplier South Korea
Tirzepatide supplier UAE
Nagpur pharmaceutical exporter
π₯ Long-Tail SEO Keywords
Mounjaro 5 mg Prefilled Pen pharmaceutical exporter from India
Tirzepatide 5 mg injection international B2B supplier
Mounjaro 5 mg injectable medicine supplier India
Tirzepatide 5 mg prefilled pen pharmaceutical exporter
Mounjaro 5 mg supplier from Nagpur India
Tirzepatide diabetes injection international supplier
Mounjaro 5 mg pharmaceutical B2B exporter
Tirzepatide injectable product exporter from India
Type 2 diabetes injectable medicine supplier India
Tirzepatide 5 mg global pharmaceutical supply
π’ Phoenix Exim Keywords
Phoenix Exim pharmaceutical exporter
Phoenix Exim medicine exporter Nagpur
Phoenix Exim Mounjaro supplier
Phoenix Exim Tirzepatide supplier India
Phoenix Exim diabetes medicine exporter
π PHOENIX EXIM β INTERNATIONAL PHARMACEUTICAL SUPPLY
Mounjaro 5 mg Prefilled Pen | Tirzepatide Injection
Phoenix Exim
Pharmaceutical Exporter from Nagpur, India
π International B2B Supply Support:
πΊπΈ USA | π¬π§ UK | π¦πΊ Australia | πΈπ¬ Singapore | π¨π¦ Canada | π°π· South Korea | π¦πͺ UAE
Keywords







